Pancreatic Cancer Therapeutics and Diagnostics Market [2031]
Pancreatic Cancer Therapeutics and Diagnostics Market [2031]
Segments - Latin America Pancreatic Cancer Therapeutics and Diagnostics Market by Types {Diagnostics (Biopsy, Endoscopy, Imaging, and others) and Treatment (Chemotherapy, Targeted Therapy, Surgery, and Others)}, and Region - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-3158
| 4.6 Rating
| 74 Reviews
| 198 Pages
| Format :
Report Description
The Latin America pancreatic cancer therapeutics and diagnostics market size was USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031, expanding at a CAGR of 5.8% during 2023–2031. The growth of the market is attributed to poor diet and unhealthy life style.
Pancreatic cancer therapeutics and diagnostics refer to medical treatments used to diagnose pancreatic cancer and then treat it. Factors such as rising frequency and incidence of pancreatic cancer, as well as advances in molecular biology, medication development, and diagnostic technologies, all play a significant role in market expansion.
Pancreatic cancer originates in the tissues of pancreas, an organ located behind the bottom section of your stomach in your belly. The pancreas generates hormones that facilitate digestion and releases enzymes that aid digestion.
A number of tumors, both malignant and noncancerous, affect the pancreas. The most common kind of pancreatic cancer begins in the cells that line the ducts that convey pancreatic digesting enzymes.
Pancreatic cancer is rarely diagnosed in its early stages, when it is most treatable. This is due to the fact that it usually does not present symptoms until it has migrated to other organs.
According to the American Cancer Society, 55,440 people were diagnosed with pancreatic cancer in the United States in 2018. Furthermore, the ACS notes that pancreatic cancer is the third greatest cause of cancer mortality in the United States and is anticipated to be the second leading cause of death in the forecasted period.
Currently large-scale screening in the general population is not considered effective for detecting the disease at an early stage, though new techniques and screening of tightly targeted groups particularly those with a family history are being investigated including blood markers for pancreatic cancer.
Pancreatic cancer is caused by a complicated and multivariate combination of factors, including cigarette smoking, diabetes, and obesity. The influence of old age and family history is dominating.
Tobacco use is strongly linked to pancreatic cancer risk, and it is believed that smoking cessation might prevent around 30% of pancreatic malignancies. A high diet of red and processed meat is linked to an increased risk of pancreatic cancer.
COVID-19 continues to have a significant influence on healthcare systems, offering several obstacles and creating a great deal of uncertainty for oncologists and cancer patients alike. Oncologists throughout the world are working on remaining up to speed with the most recent COVID-19 information and analyzing it in order to make educated and reasonable judgments about patient therapy.
During the pandemic, many patients experienced modifications or delays in their care, with more and more doctors advising them to avoid hospitals. Patients in numerous places have also claimed that their operations and treatments, including clinical studies, have been postponed or cancelled until further notice.
Market Trends, Drivers, Restraints, and Opportunities
-
Rising elderly population is expected to boost the market during the forecast period.
-
Introduction of sophisticated equipment in diagnostic procedures is projected to drive the market in the coming years.
-
High consumption of fast foods and red meat is expected to spur the market in the coming years.
-
Lack of techniques for early-stage detection of pancreatic cancer is expected to hinder the market.
-
High treatment cost act as key challenges that can hamper the market growth.
-
Technological advancements in diagnostics and treatments are projected to create lucrative opportunities for the market players.
Scope of Latin America Pancreatic Cancer Therapeutics and Diagnostics Market Report
The report on the Latin America pancreatic cancer therapeutics and diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Latin America Pancreatic Cancer Diagnostics & Therapeutics Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Types (Diagnostics (Biopsy, Endoscopy, Imaging, and others) and Treatment (Chemotherapy, Targeted Therapy, Surgery, and others) |
|
Regional Scope |
Latin America |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
F. Hoffmann-La Roche AG; Pfizer Inc; Eli Lilly; Bristol-Myers Squibb; Novartis AG |
Latin America Pancreatic Cancer Diagnostics & Therapeutics Market Segment Insights
The chemotherapy segment is expected to expand at a rapid pace
Based on types, the Latin America pancreatic cancer therapeutics and diagnostics market is divided into diagnosis and treatment. The treatment segment is further divided into chemotherapy, targeted therapy, surgery, and others. The chemotherapy segment is expected to represent a key share of the market during the forecast period owing to the use of treatments to eliminate cancer cells, generally by preventing the cancer cells from growing and dividing.
Segments
Types
- Diagnosis
- Biopsy
- Endoscopy
- Imaging
- Others
- Treatment
- Chemotherapy
- Targeted Therapy
- Surgery Therapy
- Others
Regions
-
Latin America
Key Players
- Pfizer Inc.
- Eli Lilly
- Bristol-Myers Squibb
- F. Hoffmann-La Roche Ltd
- Novartis AG
Competitive Landscape
Key players competing in the Latin America pancreatic cancer diagnostics & therapeutics market include F. Hoffmann-La Roche AG; Pfizer Inc.; Eli Lilly; Bristol-Myers Squibb; and Novartis AG.
Some of these players coming up with several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase/enhance their market shares.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Pancreatic Cancer Therapeutics and Diagnostics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pancreatic Cancer Therapeutics and Diagnostics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pancreatic Cancer Therapeutics and Diagnostics Market - Supply Chain
4.5. Global Pancreatic Cancer Therapeutics and Diagnostics Market Forecast
4.5.1. Pancreatic Cancer Therapeutics and Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pancreatic Cancer Therapeutics and Diagnostics Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Pancreatic Cancer Therapeutics and Diagnostics Market Absolute $ Opportunity
5. Global Pancreatic Cancer Therapeutics and Diagnostics Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Pancreatic Cancer Therapeutics and Diagnostics Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Pancreatic Cancer Therapeutics and Diagnostics Demand Share Forecast, 2019-2026
6. North America Pancreatic Cancer Therapeutics and Diagnostics Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Pancreatic Cancer Therapeutics and Diagnostics Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Pancreatic Cancer Therapeutics and Diagnostics Demand Share Forecast, 2019-2026
7. Latin America Pancreatic Cancer Therapeutics and Diagnostics Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Pancreatic Cancer Therapeutics and Diagnostics Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Pancreatic Cancer Therapeutics and Diagnostics Demand Share Forecast, 2019-2026
8. Europe Pancreatic Cancer Therapeutics and Diagnostics Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Pancreatic Cancer Therapeutics and Diagnostics Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Pancreatic Cancer Therapeutics and Diagnostics Demand Share Forecast, 2019-2026
9. Asia Pacific Pancreatic Cancer Therapeutics and Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Pancreatic Cancer Therapeutics and Diagnostics Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Pancreatic Cancer Therapeutics and Diagnostics Demand Share Forecast, 2019-2026
10. Middle East & Africa Pancreatic Cancer Therapeutics and Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Pancreatic Cancer Therapeutics and Diagnostics Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Pancreatic Cancer Therapeutics and Diagnostics Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Pancreatic Cancer Therapeutics and Diagnostics Market: Market Share Analysis
11.2. Pancreatic Cancer Therapeutics and Diagnostics Distributors and Customers
11.3. Pancreatic Cancer Therapeutics and Diagnostics Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Pfizer Inc.
11.4.2. Eli Lilly
11.4.3. Bristol-Myers Squibb
11.4.4. F. Hoffmann-La Roche Ltd
11.4.5. Novartis AG
Methodology
Related Reports
Some other reports from this category!
Our Clients
